{"id":8656,"date":"2025-09-18T00:34:43","date_gmt":"2025-09-17T21:34:43","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8656"},"modified":"2025-09-18T00:34:43","modified_gmt":"2025-09-17T21:34:43","slug":"heart-failure-guidelines-may-miss-risk-in-people-with-obesity","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/heart-failure-guidelines-may-miss-risk-in-people-with-obesity\/","title":{"rendered":"Heart Failure Guidelines May Miss Risk in People With Obesity"},"content":{"rendered":"<div>Heart Failure Guidelines May Miss Risk in People With Obesity<\/div>\n<div><\/div>\n<div>Source: Circulation: Heart Failure \u2013 August 28, 2025<\/div>\n<div><span> 1. Background<\/span><\/div>\n<div><span> \u2022 2022 AHA\/ACC\/HFSA HF guidelines use NT-proBNP \u2265125 pg\/mL to reclassify patients from Stage A (at-risk) \u2192 Stage B (pre-HF).<\/span><\/div>\n<div><span> \u2022 Concern: People with obesity have lower NP levels, which may underestimate risk.<\/span><\/div>\n<div><span> 2. Study Design<\/span><\/div>\n<div><span> \u2022 Analysis of &gt;32,000 adults without HF from community cohorts.<\/span><\/div>\n<div><span> \u2022 Compared classification using 2013 guidelines (no NP) vs 2022 guidelines (with NP).<\/span><\/div>\n<div><span> 3. Comparison of Guidelines<\/span><\/div>\n<div><span> \u2022 2013 guidelines: did not use natriuretic peptides (NPs).<\/span><\/div>\n<div><span> \u2022 2022 guidelines: added NP threshold (125 pg\/mL) to move patients from Stage A (at risk) \u2192 Stage B (pre-HF).<\/span><\/div>\n<div>\u2022<span> <\/span>Problem: Obese patients have naturally lower NP levels \u2192 risk may be underestimated.<\/div>\n<div><span> 4. Guideline Implications<\/span><\/div>\n<div><span> \u2022 Current single threshold (125 pg\/mL) may miss risk in obese patients.<\/span><\/div>\n<div><span> \u2022 Authors suggest lower NP cut-offs for obesity.<\/span><\/div>\n<div><span> 5. Expert Commentary:<\/span><\/div>\n<div><span> \u2022 Future guidelines may use a matrix of NP thresholds adjusted for obesity, CKD, etc.<\/span><\/div>\n<div><span> \u2022 Clinicians should consider other risk factors, not only NP levels.<\/span><\/div>\n<div><span> 6. Conclusion<\/span><\/div>\n<div><span> \u2022 NP-based classification underestimates HF risk in obesity.<\/span><\/div>\n<div><span> \u2022 Study provides evidence for refining cut-points in future HF guidelines.<\/span><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/click.mail.medscape.com\/?qs=5b178ead4680c36bcc95ca9ee530b59104e333cf61854f12a29c3db4a21fc5a796b95ca3f7e408340c397b7a43d76e4ddda959940f822264434944c364d49fbe\">https:\/\/click.mail.medscape.com\/?qs=5b178ead4680c36bcc95ca9ee530b59104e333cf61854f12a29c3db4a21fc5a796b95ca3f7e408340c397b7a43d76e4ddda959940f822264434944c364d49fbe<\/a><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Heart Failure Guidelines May Miss Risk in People With Obesity Source: Circulation: Heart Failure \u2013 August 28, 2025 1. Background \u2022 2022 AHA\/ACC\/HFSA HF guidelines use NT-proBNP \u2265125 pg\/mL to reclassify patients from Stage A (at-risk) \u2192 Stage B (pre-HF). \u2022 Concern: People with obesity have lower NP levels, which may underestimate risk. 2. Study [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8656","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8656","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8656"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8656\/revisions"}],"predecessor-version":[{"id":8657,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8656\/revisions\/8657"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8656"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8656"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}